Prostate Cancer Radiation Therapy Recommendations in Response to COVID-19
Purpose: During a global pandemic, the benefit of routine visits and treatment of patients with cancer must be weighed against the risks to patients, staff, and society. Prostate cancer is one of the most common cancers radiation oncology departments treat, and efficient resource utilization is esse...
Main Authors: | , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-11-01
|
Series: | Advances in Radiation Oncology |
Online Access: | http://www.sciencedirect.com/science/article/pii/S245210942030275X |
id |
doaj-121a21dfa8664584b6ecb10a4bf9e397 |
---|---|
record_format |
Article |
spelling |
doaj-121a21dfa8664584b6ecb10a4bf9e3972020-11-25T04:00:56ZengElsevierAdvances in Radiation Oncology2452-10942020-11-0152632Prostate Cancer Radiation Therapy Recommendations in Response to COVID-19Nicholas G. Zaorsky, MD0James B. Yu, MD1Sean M. McBride, MD2Robert T. Dess, MD3William C. Jackson, MD4Brandon A. Mahal, MD5Ronald Chen, MD6Ananya Choudhury, MD7Ann Henry, MD8Isabel Syndikus, MD9Timur Mitin, MD10Alison Tree, MD11Amar U. Kishan, MD12Daniel E. Spratt, MD13Department of Radiation Oncology, Penn State Cancer Institute, Hershey, PennsylvaniaDepartment of Therapeutic Radiology/Radiation Oncology, Yale, New Haven, ConnecticutDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New YorkDepartment of Radiation Oncology, University of Michigan, Ann Arbor, MichiganDepartment of Radiation Oncology, University of Michigan, Ann Arbor, MichiganDepartment of Radiation Oncology, Dana Farber, Boston, MassachusettsDepartment of Radiation Oncology, University of Kansas, Kansas City, KansasDivision of Cancer Sciences, University of Manchester and The Christie NHS Foundation Trust, Manchester, United KingdomDepartment of Clinical Oncology, Leeds Teaching Hospitals NHS Trust and the University of Leeds, Leeds, United KingdomDepartment of Clinical Oncology, The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool, United KingdomKnight Cancer Institute, Department of Radiation Medicine, Oregon Health and Science University, Portland, OregonRadiotherapy and Imaging Division, Institute of Cancer Research, Sutton, London, United KingdomDepartment of Radiation Oncology, UCLA, Los Angeles, CaliforniaDepartment of Radiation Oncology, University of Michigan, Ann Arbor, Michigan; Corresponding author: Daniel E. Spratt, MDPurpose: During a global pandemic, the benefit of routine visits and treatment of patients with cancer must be weighed against the risks to patients, staff, and society. Prostate cancer is one of the most common cancers radiation oncology departments treat, and efficient resource utilization is essential in the setting of a pandemic. Herein, we aim to establish recommendations and a framework by which to evaluate prostate radiation therapy management decisions. Methods and Materials: Radiation oncologists from the United States and the United Kingdom rapidly conducted a systematic review and agreed upon recommendations to safely manage patients with prostate cancer during the COVID-19 pandemic. A RADS framework was created: remote visits, and avoidance, deferment, and shortening of radiation therapy was applied to determine appropriate approaches. Results: Recommendations were provided by the National Comprehensive Cancer Network risk group regarding clinical node-positive, postprostatectomy, oligometastatic, and low-volume M1 disease. Across all prostate cancer stages, telemedicine consultations and return visits were recommended when resources/staff available. Delays in consultations and return visits of between 1 and 6 months were deemed safe based on stage of disease. Treatment can be avoided or delayed until safe for very low, low, and favorable intermediate-risk disease. Unfavorable intermediate-risk, high-risk, clinical node-positive, recurrence postsurgery, oligometastatic, and low-volume M1 disease can receive neoadjuvant hormone therapy for 4 to 6 months as necessary. Ultrahypofractionation is preferred for localized, oligometastatic, and low-volume M1, and moderate hypofractionation is preferred for postprostatectomy and clinical node positive disease. Salvage is preferred to adjuvant radiation. Conclusions: Resources can be reduced for all identified stages of prostate cancer. The RADS (remote visits, and avoidance, deferment, and shortening of radiation therapy) framework can be applied to other disease sites to help with decision making in a global pandemic.http://www.sciencedirect.com/science/article/pii/S245210942030275X |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Nicholas G. Zaorsky, MD James B. Yu, MD Sean M. McBride, MD Robert T. Dess, MD William C. Jackson, MD Brandon A. Mahal, MD Ronald Chen, MD Ananya Choudhury, MD Ann Henry, MD Isabel Syndikus, MD Timur Mitin, MD Alison Tree, MD Amar U. Kishan, MD Daniel E. Spratt, MD |
spellingShingle |
Nicholas G. Zaorsky, MD James B. Yu, MD Sean M. McBride, MD Robert T. Dess, MD William C. Jackson, MD Brandon A. Mahal, MD Ronald Chen, MD Ananya Choudhury, MD Ann Henry, MD Isabel Syndikus, MD Timur Mitin, MD Alison Tree, MD Amar U. Kishan, MD Daniel E. Spratt, MD Prostate Cancer Radiation Therapy Recommendations in Response to COVID-19 Advances in Radiation Oncology |
author_facet |
Nicholas G. Zaorsky, MD James B. Yu, MD Sean M. McBride, MD Robert T. Dess, MD William C. Jackson, MD Brandon A. Mahal, MD Ronald Chen, MD Ananya Choudhury, MD Ann Henry, MD Isabel Syndikus, MD Timur Mitin, MD Alison Tree, MD Amar U. Kishan, MD Daniel E. Spratt, MD |
author_sort |
Nicholas G. Zaorsky, MD |
title |
Prostate Cancer Radiation Therapy Recommendations in Response to COVID-19 |
title_short |
Prostate Cancer Radiation Therapy Recommendations in Response to COVID-19 |
title_full |
Prostate Cancer Radiation Therapy Recommendations in Response to COVID-19 |
title_fullStr |
Prostate Cancer Radiation Therapy Recommendations in Response to COVID-19 |
title_full_unstemmed |
Prostate Cancer Radiation Therapy Recommendations in Response to COVID-19 |
title_sort |
prostate cancer radiation therapy recommendations in response to covid-19 |
publisher |
Elsevier |
series |
Advances in Radiation Oncology |
issn |
2452-1094 |
publishDate |
2020-11-01 |
description |
Purpose: During a global pandemic, the benefit of routine visits and treatment of patients with cancer must be weighed against the risks to patients, staff, and society. Prostate cancer is one of the most common cancers radiation oncology departments treat, and efficient resource utilization is essential in the setting of a pandemic. Herein, we aim to establish recommendations and a framework by which to evaluate prostate radiation therapy management decisions. Methods and Materials: Radiation oncologists from the United States and the United Kingdom rapidly conducted a systematic review and agreed upon recommendations to safely manage patients with prostate cancer during the COVID-19 pandemic. A RADS framework was created: remote visits, and avoidance, deferment, and shortening of radiation therapy was applied to determine appropriate approaches. Results: Recommendations were provided by the National Comprehensive Cancer Network risk group regarding clinical node-positive, postprostatectomy, oligometastatic, and low-volume M1 disease. Across all prostate cancer stages, telemedicine consultations and return visits were recommended when resources/staff available. Delays in consultations and return visits of between 1 and 6 months were deemed safe based on stage of disease. Treatment can be avoided or delayed until safe for very low, low, and favorable intermediate-risk disease. Unfavorable intermediate-risk, high-risk, clinical node-positive, recurrence postsurgery, oligometastatic, and low-volume M1 disease can receive neoadjuvant hormone therapy for 4 to 6 months as necessary. Ultrahypofractionation is preferred for localized, oligometastatic, and low-volume M1, and moderate hypofractionation is preferred for postprostatectomy and clinical node positive disease. Salvage is preferred to adjuvant radiation. Conclusions: Resources can be reduced for all identified stages of prostate cancer. The RADS (remote visits, and avoidance, deferment, and shortening of radiation therapy) framework can be applied to other disease sites to help with decision making in a global pandemic. |
url |
http://www.sciencedirect.com/science/article/pii/S245210942030275X |
work_keys_str_mv |
AT nicholasgzaorskymd prostatecancerradiationtherapyrecommendationsinresponsetocovid19 AT jamesbyumd prostatecancerradiationtherapyrecommendationsinresponsetocovid19 AT seanmmcbridemd prostatecancerradiationtherapyrecommendationsinresponsetocovid19 AT roberttdessmd prostatecancerradiationtherapyrecommendationsinresponsetocovid19 AT williamcjacksonmd prostatecancerradiationtherapyrecommendationsinresponsetocovid19 AT brandonamahalmd prostatecancerradiationtherapyrecommendationsinresponsetocovid19 AT ronaldchenmd prostatecancerradiationtherapyrecommendationsinresponsetocovid19 AT ananyachoudhurymd prostatecancerradiationtherapyrecommendationsinresponsetocovid19 AT annhenrymd prostatecancerradiationtherapyrecommendationsinresponsetocovid19 AT isabelsyndikusmd prostatecancerradiationtherapyrecommendationsinresponsetocovid19 AT timurmitinmd prostatecancerradiationtherapyrecommendationsinresponsetocovid19 AT alisontreemd prostatecancerradiationtherapyrecommendationsinresponsetocovid19 AT amarukishanmd prostatecancerradiationtherapyrecommendationsinresponsetocovid19 AT danielesprattmd prostatecancerradiationtherapyrecommendationsinresponsetocovid19 |
_version_ |
1724448431074705408 |